# Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

> **NCT06904248** · PHASE3 · COMPLETED · sponsor: **Yangtze River Pharmaceutical Group Co., Ltd.** · enrollment: 224 (actual)

## Conditions studied

- Participants With Acute Moderate to Severe Pain Following Abdominal Surgery

## Interventions

- **DRUG:** Meloxicam Injection
- **DRUG:** Sodium Chloride Injection

## Key facts

- **NCT ID:** NCT06904248
- **Lead sponsor:** Yangtze River Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-29
- **Primary completion:** 2024-11-20
- **Final completion:** 2025-02-10
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904248, "Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06904248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*